Lifastuzumab(CAT: I040848) is an investigational monoclonal antibody designed to target specific tumor-associated antigens for cancer therapy. It is being explored for its potential in oncology research, particularly in antibody-drug conjugate (ADC) development, where it delivers cytotoxic agents directly to cancer cells while minimizing off-target effects. Lifastuzumab’s mechanism of action enhances tumor cell destruction while preserving healthy tissues, making it a promising candidate for precision medicine in solid tumors and hematologic malignancies. With its high specificity and targeted therapeutic potential, Lifastuzumab contributes to advancements in cancer immunotherapy and personalized treatment strategies.
